Bruker stock gained 2.10 percent as Q2 margins widened

Published on 10/05/2026 at 09:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bruker stock was last at USD 63.24 on October 2, 2026, while Guggenheim lifted its target to USD 72 from USD 70. Q2 adjusted EPS reached USD 0.49.

BRKR, US1167941087, Illustration mit AI erstellt.

Bruker stock (ISIN US1167941087) was last at USD 63.24 on Nasdaq on October 2, 2026, after gaining 2.10 percent in the session. The company delivered USD 0.49 in non-GAAP diluted EPS for Q2 2026, compared with a USD 0.38 consensus estimate, according to StockTitan in its August 4, 2026 filing summary.

Q2 EPS beat revenue estimate

Bruker reported Q2 2026 revenue of USD 838.5 million, up 5.2 percent from the prior-year quarter, but below the USD 853.57 million analyst estimate cited by MarketBeat. The result therefore combines an earnings beat with a top-line miss, a distinction that matters for a company exposed to academic, biopharma, semiconductor and energy research demand.

GAAP diluted EPS was a loss of USD 0.41 in Q2 2026, while non-GAAP operating margin reached 14.1 percent. The company also reported first-half revenue of USD 1.6619 billion and reaffirmed non-GAAP fiscal 2026 EPS guidance of USD 2.10 to USD 2.15, according to StockTitan.

Analyst target reaches USD 72

Guggenheim raised its Bruker price target to USD 72 from USD 70 while maintaining a Buy rating on October 1, 2026, as reported by Markets Insider. The revised target stands USD 8.76 above the October 2 price, a 13.9 percent premium calculated from USD 63.24.

The broader analyst picture is more cautious. MarketBeat reported a Hold consensus from 14 brokerages, comprising six Buy ratings, five Holds, two Sells and one Strong Buy, with an average 12-month target of USD 57.00. That average is USD 6.24 below the October 2 price, or 9.9 percent lower.

Stock stays below yearly high

Bruker traded between USD 62.25 and USD 64.36 on October 2, 2026, with volume of 2,227,601 shares. Its 52-week range was USD 32.37 to USD 66.98, while market capitalization stood at USD 9.6 billion, placing the share 5.6 percent below the yearly high.

For investors, the central tension is visible in the numbers: non-GAAP EPS beat expectations and margins improved, while revenue missed the estimate and the average analyst target remains below the latest price.